Puberty blockers used for precocious puberty and gender dysphoria are the same medications, primarily GnRH analogues such as leuprorelin and triptorelin. The clinical contexts differ, but the pharmacology does not. Dosages, administration routes, and side-effect profiles are broadly comparable across both uses, and the medications have decades of safety data behind them.
What are puberty blockers, exactly?
GnRH analogues, gonadotrophin-releasing hormone analogues, work by continuously stimulating GnRH receptors in the pituitary gland. That continuous stimulation, paradoxically, causes the pituitary to stop responding. The result is that the hormonal cascade that drives puberty, the release of luteinising hormone and follicle-stimulating hormone, is paused. Without that cascade, the gonads do not produce the levels of oestrogen or testosterone that drive pubertal development.
The medications most commonly used are leuprorelin (also known as leuprolide), triptorelin, and histrelin. They are available as injections given every four weeks, as longer-acting depot injections given every three months, and as subcutaneous implants that last around a year. These are not new drugs invented for gender medicine. They have been the standard of care for precocious puberty since the 1980s.
Precocious puberty: how puberty blockers are used
Precocious puberty is the medical term for puberty that begins significantly earlier than typical: before around eight in those assigned female at birth, and before around nine in those assigned male at birth. It can cause physical and psychological distress, affect adult height, and create social difficulties for children who are visibly developing years ahead of their peers.
In this context, GnRH analogues are prescribed to pause the process. The goal is to halt development until the child reaches an age at which puberty is age-appropriate, at which point the medication is stopped and puberty resumes, usually within a few months. The treatment is widely accepted, largely uncontroversial, and is available through mainstream paediatric endocrinology services across most countries.
Dosages vary by the child's size and the preparation used. A typical leuprorelin depot dose for precocious puberty might be 3.75 mg every four weeks, or 11.25 mg every three months, adjusted by body weight in younger or smaller children. Triptorelin is similarly dosed in monthly or three-monthly preparations. These figures give a useful reference point when comparing to the gender dysphoria context.
Gender dysphoria: how puberty blockers are used
For a trans young person experiencing gender dysphoria, the purpose of puberty blockers is different but the mechanism is the same: pause the hormonal cascade driving puberty. The aim is to prevent the development of secondary sex characteristics that the young person finds deeply distressing, and to give them time, alongside psychological support, to consider their options before any further steps.
The medications used are the same ones: leuprorelin, triptorelin, histrelin. The doses are comparable to those used in precocious puberty, sometimes modestly higher because the young person may already be further into puberty when treatment begins. The delivery methods are identical: monthly injections, three-monthly depots, or annual implants.
Unlike precocious puberty treatment, puberty blockers in gender dysphoria are not followed by allowing the same puberty to resume. They are either continued while the young person and their clinical team consider gender-affirming hormones, or stopped if the person decides that is not the direction they want to go, in which case puberty resumes within months. The blocker itself is reversible: the question of what comes next is a separate decision made later, with more information, by a young person who has had time to think.
Are the dosages actually the same?
Yes, broadly. The dosing protocols used in gender dysphoria follow the same pharmacological principles as those used in precocious puberty. Endocrine Society guidelines on gender-affirming care in adolescents recommend doses within the same ranges used in paediatric endocrinology. There is no special high-dose protocol invented for trans young people, no fundamentally different preparation, and no departure from established prescribing norms.
What varies is the stage of puberty at which treatment begins. A child treated for precocious puberty may be six or seven. A trans young person may be starting treatment at eleven, twelve, or thirteen, already partway through pubertal development. The latter may need a somewhat higher dose to achieve adequate suppression, but the medication and the mechanism are the same.
How do the side effects compare?
The side-effect profile of GnRH analogues is linked to the medication and its mechanism, not to the clinical indication. In both contexts, the known and monitored side effects include:
- Reduced bone mineral density during the period of use. This is monitored with regular bone density scans in both precocious puberty and gender dysphoria protocols, and density generally recovers or continues to develop appropriately once treatment ends or is followed by gender-affirming hormones.
- Mood changes. Some young people report low mood or emotional changes during blocker use. This is noted in both clinical contexts and is subject to monitoring and support.
- Hot flushes or injection-site reactions, which are common with any depot injection and are generally mild.
- Possible effects on height trajectory, which is why monitoring growth is standard practice.
What the evidence does not show is a categorically different or worse side-effect profile in the gender dysphoria context compared to the precocious puberty context. The Endocrine Society, WPATH's Standards of Care 8, and the international paediatric endocrinology literature all describe broadly similar risk profiles across both uses.
The claim that puberty blockers are somehow more dangerous when used for gender dysphoria than when used for precocious puberty has no pharmacological basis. A molecule does not behave differently because of the reason a doctor prescribed it.
Why does the controversy exist at all?
The medical controversy around puberty blockers in gender care is not driven by evidence of a different risk profile. The same medications, prescribed by paediatric endocrinologists for precocious puberty, attract no political attention at all. The moment the same drug is used to support a trans young person, it is described in public debate as experimental, dangerous, or irreversible.
None of those descriptions are pharmacologically accurate. The medications are the same, the monitoring is the same, the reversibility is the same, and the decades of safety data are the same. What is different is the identity of the young person being treated, and the political climate in which that treatment is being debated.
In the UK, the sale and supply of puberty blockers on private prescription for trans young people has been banned, causing serious harm to trans young people and their families. Other countries have followed with similar restrictions. These bans have not been accompanied by equivalent restrictions on prescribing the same medications for precocious puberty, which makes the stated clinical rationale for the ban extraordinarily difficult to sustain.
What does the evidence actually say?
The Endocrine Society has published guidelines on the endocrine treatment of gender-dysphoric and gender-incongruent people that describe puberty blockers as a safe and effective way to give young people time to explore their gender identity without the distress of irreversible pubertal changes. WPATH's Standards of Care 8 supports their use within a multidisciplinary care framework. These are the major international bodies in this field, and their positions reflect the evidence base available to them.
The Cass Review, which led to the UK ban, has been widely criticised internationally by gender specialists, researchers, and clinicians. The methodology, the citation practices, and the conclusions have all been challenged. I do not cite it approvingly, and neither do many of the researchers and clinicians who work in this field globally.
The honest picture is this: puberty blockers have a real and monitored side-effect profile that any clinician should discuss openly with a young person and their family. Bone density, mood, and growth need watching. These are not trivial considerations, and good care addresses them. But they are the same considerations in precocious puberty and in gender dysphoria, addressed through the same monitoring protocols, using the same medications, because the medications are the same.
What should a parent or young person take from this?
If you are trying to understand what puberty blockers actually are, and how they actually work, the most useful thing to remember is this: these are not new, experimental, or uniquely risky medications. They have been used safely in children for decades. The version used in gender dysphoria is not a different drug or a more aggressive dose. It is the same treatment, given in a different clinical context, to a young person who deserves the same quality of care as any other child whose puberty needs medical management.
The political noise around this topic is loud and often deliberately frightening. The pharmacology is far quieter and far more reassuring than that noise suggests. A young person who needs time before puberty reshapes their body in ways they cannot undo deserves access to the same tools that have been available to other children for forty years. Withholding those tools is not a neutral act. It is a decision with consequences, and those consequences fall entirely on the young person.
If there is a topic that you would like me to cover, just let Sammy know.
Dr Helen Webberley is a Gender Specialist, Medical Educator, writer, and advocate, and the founder of GenderGP. She writes about gender identity, trans healthcare, and the lives of trans and gender-diverse people.
Comments